Successful treatment of intravenously abused oral Opana ER‐induced thrombotic microangiopathy without plasma exchange
Open Access
- 25 March 2014
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 89 (7) , 695-697
Abstract
In January 2013, the Centers for Disease Control and Prevention reported an illness associated with intravenous (IV) abuse of oral Opana ER (oxymorphone) in Tennessee. The clinical presentation of this syndrome was reported to resemble that of thrombotic thrombocytopenic purpura in the 15 patients reported; 12 were treated with plasma exchange. We report a similar case series of 15 patients with 18 episodes of thrombotic microangiopathy associated with recent IV abuse of oral Opana ER. In our series, we demonstrate that therapeutic plasma exchange is unnecessary; supportive care and treatment of underlying infections and renal dysfunction (without use of plasma exchange) resulted in clinical improvement in all patients. Thus, it appears that plasma exchange with associated costs and risks can be safely omitted in patients with thrombotic microangiopathy resulting from IV abuse of oral Opana ER. Am. J. Hematol. 89:695–697, 2014.Keywords
This publication has 4 references indexed in Scilit:
- Plasma Exchange Is Not Necessary For The Treatment Of Microangiopathic Hemolytic Anemia Due To Intravenous Opana AbuseBlood, 2013
- Opana-ER used the wrong way: intravenous abuse leading to microangiopathic hemolysis and a TTP-like syndromeBlood, 2013
- Drug-Associated Thrombotic MicroangiopathiesSeminars in Thrombosis and Hemostasis, 2012
- Rapid quantitative assay of ADAMTS13 activity on an automated coagulation analyzer: Clinical applications and comparison with immunoblot methodAmerican Journal of Hematology, 2008